BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37823726)

  • 21. Targeted RNA-Sequencing Enables Detection of Relevant Translocations and Single Nucleotide Variants and Provides a Method for Classification of Hematological Malignancies-RANKING.
    de Lange K; de Boer EN; Bosga A; Alimohamed MZ; Johansson LF; Mulder AB; Vellenga E; van Diemen CC; Deelen P; van den Berg E; Sikkema-Raddatz B
    Clin Chem; 2020 Dec; 66(12):1521-1530. PubMed ID: 33257979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting oncogenic Ras signaling in hematologic malignancies.
    Ward AF; Braun BS; Shannon KM
    Blood; 2012 Oct; 120(17):3397-406. PubMed ID: 22898602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
    Borthakur G; Popplewell L; Boyiadzis M; Foran J; Platzbecker U; Vey N; Walter RB; Olin R; Raza A; Giagounidis A; Al-Kali A; Jabbour E; Kadia T; Garcia-Manero G; Bauman JW; Wu Y; Liu Y; Schramek D; Cox DS; Wissel P; Kantarjian H
    Cancer; 2016 Jun; 122(12):1871-9. PubMed ID: 26990290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution.
    Ainciburu M; Ezponda T; Berastegui N; Alfonso-Pierola A; Vilas-Zornoza A; San Martin-Uriz P; Alignani D; Lamo-Espinosa J; San-Julian M; Jiménez-Solas T; Lopez F; Muntion S; Sanchez-Guijo F; Molero A; Montoro J; Serrano G; Diaz-Mazkiaran A; Lasaga M; Gomez-Cabrero D; Diez-Campelo M; Valcarcel D; Hernaez M; Romero JP; Prosper F
    Elife; 2023 Jan; 12():. PubMed ID: 36629404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.
    Chen J; Facchinetti F; Braye F; Yurchenko AA; Bigot L; Ponce S; Planchard D; Gazzah A; Nikolaev S; Michiels S; Vasseur D; Lacroix L; Tselikas L; Nobre C; Olaussen KA; Andre F; Scoazec JY; Barlesi F; Soria JC; Loriot Y; Besse B; Friboulet L
    Ann Oncol; 2022 Apr; 33(4):434-444. PubMed ID: 35066105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Chen EC; Li S; Eisfeld AK; Luskin MR; Mims A; Jones D; Antin JH; Cutler CS; Koreth J; Ho VT; Gooptu M; Romee R; El-Jawahri A; McAfee SL; DeFilipp Z; Soiffer RJ; Chen YB; Fathi AT
    Transplant Cell Ther; 2021 Jun; 27(6):479.e1-479.e7. PubMed ID: 33840625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.
    Thol F; Weissinger EM; Krauter J; Wagner K; Damm F; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
    Haematologica; 2010 Oct; 95(10):1668-74. PubMed ID: 20494930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
    Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
    Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.
    Tyner JW; Erickson H; Deininger MW; Willis SG; Eide CA; Levine RL; Heinrich MC; Gattermann N; Gilliland DG; Druker BJ; Loriaux MM
    Blood; 2009 Feb; 113(8):1749-55. PubMed ID: 19075190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Platt MY; Fathi AT; Borger DR; Brunner AM; Hasserjian RP; Balaj L; Lum A; Yip S; Dias-Santagata D; Zheng Z; Le LP; Graubert TA; Iafrate AJ; Nardi V
    J Mol Diagn; 2015 Nov; 17(6):661-8. PubMed ID: 26331834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors.
    Zorzan E; Hanssens K; Giantin M; Dacasto M; Dubreuil P
    PLoS One; 2015; 10(11):e0142450. PubMed ID: 26562302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Epigenetic therapy for hematologic malignancies].
    Kobayashi Y
    Rinsho Ketsueki; 2015 Oct; 56(10):2015-23. PubMed ID: 26458440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wild-type Kras expands and exhausts hematopoietic stem cells.
    Sasine JP; Himburg HA; Termini CM; Roos M; Tran E; Zhao L; Kan J; Li M; Zhang Y; de Barros SC; Rao DS; Counter CM; Chute JP
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C.
    Cannataro VL; Gaffney SG; Stender C; Zhao ZM; Philips M; Greenstein AE; Townsend JP
    Oncogene; 2018 May; 37(18):2444-2455. PubMed ID: 29453361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma.
    Doll S; Urisman A; Oses-Prieto JA; Arnott D; Burlingame AL
    Mol Cell Proteomics; 2017 Jan; 16(1):39-56. PubMed ID: 27834733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras.
    Xu J; Hedberg C; Dekker FJ; Li Q; Haigis KM; Hwang E; Waldmann H; Shannon K
    Blood; 2012 Jan; 119(4):1032-5. PubMed ID: 22144181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-cell RNA-seq reveals a distinct transcriptome signature of aneuploid hematopoietic cells.
    Zhao X; Gao S; Wu Z; Kajigaya S; Feng X; Liu Q; Townsley DM; Cooper J; Chen J; Keyvanfar K; Fernandez Ibanez MDP; Wang X; Young NS
    Blood; 2017 Dec; 130(25):2762-2773. PubMed ID: 29030335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.
    Kundu S; Ali MA; Handin N; Conway LP; Rendo V; Artursson P; He L; Globisch D; Sjöblom T
    J Exp Clin Cancer Res; 2021 Jul; 40(1):225. PubMed ID: 34233735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.
    Zhao A; Zhou H; Yang J; Li M; Niu T
    Signal Transduct Target Ther; 2023 Feb; 8(1):71. PubMed ID: 36797244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prognostic risk prediction model based on ferroptosis-related long non-coding RNAs in bladder cancer: A bulk RNA-seq research and scRNA-seq validation.
    Xiang X; Guo Y; Chen Z; Zhang F; Huang J; Qin Y
    Medicine (Baltimore); 2022 Dec; 101(51):e32558. PubMed ID: 36595859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.